Resverlogix Corp (RVXCF) 1.2800 $RVXCF Resverlo
Post# of 273242
Posted On: 09/21/2016 5:09:46 AM
Resverlogix Corp (RVXCF) 1.2800 $RVXCF
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
PR Newswire - Wed Sep 14, 5:35PM CDT
Resverlogix Corp. ("Resverlogix" or the "Company"
(TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing ir@resverlogix.com.
RVX.TO: 1.76 (+0.13)
Resverlogix Announces Participation in Upcoming Conferences
PR Newswire - Mon Sep 12, 6:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company" (TSX:RVX) is pleased to announce its participation in the following industry conferences in the month of September.
RVX.TO: 1.76 (+0.13)
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
PR Newswire - Mon Aug 29, 10:03AM CDT
The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes.
RVX.TO: 1.76 (+0.13)
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
PR Newswire - Thu Aug 11, 6:00AM CDT
A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned without any modification.
RVX.TO: 1.76 (+0.13)
The Life Sciences Report Examines Resverlogix's New Trial
Marketwired - Thu Aug 04, 8:01AM CDT
SAN FRANCISCO, CA--(Marketwired - August 04, 2016) - With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix Corp. (TSX: RVX) has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications.
RVX.TO: 1.76 (+0.13)
Zenith Epigenetics Corp. Announces Name Change and Internal Corporate Reorganization
PR Newswire - Tue Aug 02, 8:00AM CDT
Zenith Epigenetics Corp. ("Zenith" or the "Company" announced today that it has changed its name to Zenith Capital Corp. concurrent with the internal corporate reorganization which the Company has determined will be effective on August 1, 2016. The name change and reorganization were approved by shareholders at the annual and special meeting of shareholders held on January 7, 2016.
Resverlogix Files 2016 Year-End Disclosure Documents
PR Newswire - Wed Jul 27, 5:43PM CDT
Resverlogix Corp. ("Resverlogix" or the "Company" (TSX:RVX) announced today that it filed its audited Consolidated Financial Statements for the year ended April 30, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. The Company has also filed its Annual Information Form for the year ended April 30, 2016. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing ir@resverlogix.com.
RVX.TO: 1.76 (+0.13)
Resverlogix Announces Corporate Update Webcast
PR Newswire - Thu Jun 09, 1:15PM CDT
Resverlogix Corp. ("Resverlogix" (TSX:RVX) announces it will be hosting a corporate update via webcast on Monday, June 13, 2016 at 11:00 am MT / 1:00 pm ET. Mr. Donald McCaffrey, President and Chief Executive Officer will present an update and overview of recent activities.
RVX.TO: 1.76 (+0.13)
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
PR Newswire - Thu Jun 02, 7:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company" (TSX:RVX) is pleased to announce that findings of a study performed by the Baker IDI Heart and Diabetes Institute and Resverlogix has been published in the journal 'Metabolism', titled: "Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial."
RVX.TO: 1.76 (+0.13)
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
PR Newswire - Tue May 24, 5:54PM CDT
"Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor that significantly decreases abundance and activity of complement proteins"
RVX.TO: 1.76 (+0.13)
The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium
PR Newswire - Mon Apr 18, 7:30AM CDT
Resverlogix to chair and present at The New York Academy of Sciences' symposium "Epigenetics: Cancer & Beyond"
RVX.TO: 1.76 (+0.13)
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
PR Newswire - Mon Jan 25, 12:41PM CST
Resverlogix Corp. (the "Corporation" (TSX:RVX) today announced the acceptance for publication of a manuscript titled: "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease," in the journal "Atherosclerosis".
RVX.TO: 1.76 (+0.13)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/t6wjrw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview - Therapeutics Development - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development - Alvogen Korea - AnGes MG, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Hemostemix Ltd - Mesoblast Limited - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Symic Biomedical, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. - Yuyu Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/t6wjrw/peripheral
MESO: 4.42 (+0.06), AZN: 33.65 (+0.13), ATHX: 1.98 (+0.01), PRTO: 8.43 (-0.33), CELGZ: 1.20 (unch)
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015
M2 - Thu Jan 14, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z9cx7q/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering. The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma, Inc. - Angion Biomedica Corp. - Apceth GmbH & Co. KG - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Complexa, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Lupin Limited - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prismic Pharmaceuticals, Inc. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - RegenMedTX, LLC - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Thrasos Therapeutics Inc. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/z9...nic_kidney
LLY: 79.88 (+0.72), ISIS: 57.56 (-0.28), OPK: 10.50 (+0.19), ICPT: 170.01 (+13.27), XLRN: 37.48 (+0.98)
Resverlogix Corp. Product Pipeline Review-2015 : Acute Market Reports
M2 - Fri Dec 18, 6:13AM CST
Acute Market Reports's, 'Resverlogix Corp. - Product Pipeline Review - 2015', provides an overview of the Resverlogix Corp.'s pharmaceutical research and development focus.
Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
PR Newswire - Wed Nov 11, 9:25AM CST
First patient randomized in BETonMACE Phase 3 trial in high-risk coronary artery disease and type 2 diabetes mellitus patients
RVX.TO: 1.76 (+0.13)
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
PR Newswire - Mon Oct 26, 6:00AM CDT
Apabetalone will be evaluated in a Phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients
RVX.TO: 1.76 (+0.13)
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
PR Newswire - Wed Sep 14, 5:35PM CDT
Resverlogix Corp. ("Resverlogix" or the "Company"
(TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing ir@resverlogix.com. RVX.TO: 1.76 (+0.13)
Resverlogix Announces Participation in Upcoming Conferences
PR Newswire - Mon Sep 12, 6:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company"
(TSX:RVX) is pleased to announce its participation in the following industry conferences in the month of September. RVX.TO: 1.76 (+0.13)
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
PR Newswire - Mon Aug 29, 10:03AM CDT
The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes.
RVX.TO: 1.76 (+0.13)
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
PR Newswire - Thu Aug 11, 6:00AM CDT
A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned without any modification.
RVX.TO: 1.76 (+0.13)
The Life Sciences Report Examines Resverlogix's New Trial
Marketwired - Thu Aug 04, 8:01AM CDT
SAN FRANCISCO, CA--(Marketwired - August 04, 2016) - With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix Corp. (TSX: RVX) has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications.
RVX.TO: 1.76 (+0.13)
Zenith Epigenetics Corp. Announces Name Change and Internal Corporate Reorganization
PR Newswire - Tue Aug 02, 8:00AM CDT
Zenith Epigenetics Corp. ("Zenith" or the "Company"
announced today that it has changed its name to Zenith Capital Corp. concurrent with the internal corporate reorganization which the Company has determined will be effective on August 1, 2016. The name change and reorganization were approved by shareholders at the annual and special meeting of shareholders held on January 7, 2016. Resverlogix Files 2016 Year-End Disclosure Documents
PR Newswire - Wed Jul 27, 5:43PM CDT
Resverlogix Corp. ("Resverlogix" or the "Company"
(TSX:RVX) announced today that it filed its audited Consolidated Financial Statements for the year ended April 30, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. The Company has also filed its Annual Information Form for the year ended April 30, 2016. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing ir@resverlogix.com. RVX.TO: 1.76 (+0.13)
Resverlogix Announces Corporate Update Webcast
PR Newswire - Thu Jun 09, 1:15PM CDT
Resverlogix Corp. ("Resverlogix"
(TSX:RVX) announces it will be hosting a corporate update via webcast on Monday, June 13, 2016 at 11:00 am MT / 1:00 pm ET. Mr. Donald McCaffrey, President and Chief Executive Officer will present an update and overview of recent activities. RVX.TO: 1.76 (+0.13)
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
PR Newswire - Thu Jun 02, 7:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company"
(TSX:RVX) is pleased to announce that findings of a study performed by the Baker IDI Heart and Diabetes Institute and Resverlogix has been published in the journal 'Metabolism', titled: "Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial." RVX.TO: 1.76 (+0.13)
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
PR Newswire - Tue May 24, 5:54PM CDT
"Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor that significantly decreases abundance and activity of complement proteins"
RVX.TO: 1.76 (+0.13)
The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium
PR Newswire - Mon Apr 18, 7:30AM CDT
Resverlogix to chair and present at The New York Academy of Sciences' symposium "Epigenetics: Cancer & Beyond"
RVX.TO: 1.76 (+0.13)
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
PR Newswire - Mon Jan 25, 12:41PM CST
Resverlogix Corp. (the "Corporation"
(TSX:RVX) today announced the acceptance for publication of a manuscript titled: "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease," in the journal "Atherosclerosis". RVX.TO: 1.76 (+0.13)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/t6wjrw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview - Therapeutics Development - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development - Alvogen Korea - AnGes MG, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Hemostemix Ltd - Mesoblast Limited - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Symic Biomedical, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. - Yuyu Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/t6wjrw/peripheral
MESO: 4.42 (+0.06), AZN: 33.65 (+0.13), ATHX: 1.98 (+0.01), PRTO: 8.43 (-0.33), CELGZ: 1.20 (unch)
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015
M2 - Thu Jan 14, 5:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/z9cx7q/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015" report to their offering. The report Chronic Kidney Disease (Chronic Renal Failure) provides an overview of its therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma, Inc. - Angion Biomedica Corp. - Apceth GmbH & Co. KG - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Complexa, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - Isis Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Lupin Limited - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prismic Pharmaceuticals, Inc. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - RegenMedTX, LLC - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Thrasos Therapeutics Inc. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/z9...nic_kidney
LLY: 79.88 (+0.72), ISIS: 57.56 (-0.28), OPK: 10.50 (+0.19), ICPT: 170.01 (+13.27), XLRN: 37.48 (+0.98)
Resverlogix Corp. Product Pipeline Review-2015 : Acute Market Reports
M2 - Fri Dec 18, 6:13AM CST
Acute Market Reports's, 'Resverlogix Corp. - Product Pipeline Review - 2015', provides an overview of the Resverlogix Corp.'s pharmaceutical research and development focus.
Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
PR Newswire - Wed Nov 11, 9:25AM CST
First patient randomized in BETonMACE Phase 3 trial in high-risk coronary artery disease and type 2 diabetes mellitus patients
RVX.TO: 1.76 (+0.13)
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
PR Newswire - Mon Oct 26, 6:00AM CDT
Apabetalone will be evaluated in a Phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients
RVX.TO: 1.76 (+0.13)
(0)
(0)Scroll down for more posts ▼